fatigue on retatrutide UK Guide: Key Facts the New Weight-Loss Drug Retatrutide #retatrutide is it safe?

PlexusDx offers oral and microdose GLP-1 options that some patients tolerate better than standard injections, providing flexibility if extreme tiredness emerges

(2025) T2DM: 46.5% discontinued by 1 year 64.1% discontinued by 2 years Without T2DM: 64.8% discontinued by 1 year 84.4% discontinued by 2 years Key Factors Linked to Discontinuation: Higher rates among patients without T2DM Age 65 years More likely to discontinue Higher weight loss during treatment Associated with lower discontinuation rates Moderate to severe GI side effects Higher likelihood of stopping treatment Higher income (T2DM only) Lower discontinuation rates Reinitiation of GLP-1: Source: Rodriguez PJ, Zhang V, Gratzl S, et al

Drinks feel stronger

PubMed Fletcher, M.M., Halls, M.L., Christopoulos, A., Sexton, P.M., & Wootten, D